WINNIPEG, Manitoba, April 29, 2021 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), is pleased to announce that it has published strong positive results from a recent consumer trial of its DermaKB™ products.

Kane Biotech recently published on its website (link to report) the results of a significant consumer trial which began in November, 2020 and ended in January, 2021. Over 4500 participants signed up for the trial, with 1,402 filling out and submitting the questionnaire. Overall, the results were compelling with an average of 82% of participants seeing an improvement in their symptoms using both the Detoxifier and the Shampoo, with an average 33% reduction in the severity of symptoms after using only a three oz. sample of either product. Results of the trial are also available on the DermaKB™ website.

“Over 4,000 participants is a huge consumer trial by anyone’s standard,” explained Kane’s Chief Scientific Officer, Gordon Guay, PhD. “Having that many people register for the trial without any compensation implies there is still a significant need in the market for this type of product. Achieving these results after using such a small amount of sample product is very compelling. Even more remarkable is the result that of those participants who identified the leading dandruff shampoo as their most often used shampoo prior to the trial, 63% said they preferred DermaKB™ products, either individually or combined after the trial.”

Investors interested in hearing more from Gordon Guay can review a video posted on the Kane Biotech website (link to video).